EGFR and non-small cell lung carcinoma: The CHRYSALIS Phase I study utilized amivantamab in EGFR exon 20 insertion-mutated NSCLC progressing on platinum chemotherapy and reported an overall response rate (ORR) of 40% and a median duration of response (DoR) of 11.1 months [43].